<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01541267</url>
  </required_header>
  <id_info>
    <org_study_id>ST-4/Aliskiren/2011</org_study_id>
    <nct_id>NCT01541267</nct_id>
  </id_info>
  <brief_title>The Effect of Various Types of the Renin-angiotensin-aldosterone System Blockade on Proteinuria</brief_title>
  <official_title>The Effect of Various Types of the Renin-angiotensin-aldosterone System Blockade on Proteinuria in Chronic Non-diabetic Kidney Disease: a Double-blind Cross-over Randomised Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Gdansk</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Gdansk</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of the study is to compare the effects of three different types of RAAS
      blockade on 24 hours proteinuria in patients with non-diabetic chronic kidney disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pharmacological blockade of the renin-angiotensin-aldosterone system (RAAS) is the main
      target of therapy to reduces both proteinuria and the rate of decline of the glomerular
      filtration rate in non-diabetic chronic renal diseases. Despite recent progress, however,
      there is still no optimal therapy that can stop the progression of these nephropathies.
      Therefore, it is necessary to optimize such treatment for further improving renal outcome.

      The aim of the present study was to compare the effects of three different types of RAAS
      blockade: (1) mineralocorticoid receptor blocker (MRB) + angiotensin receptor antagonist
      (ARA); (2) direct renin inhibitor (DRI) + ARA and (3) double maximal dose of ARA on 24 hours
      proteinuria in patients with non-diabetic chronic kidney disease
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in urinary albumin-to-creatinine ratio (UACR) between treatment arms</measure>
    <time_frame>baseline and the end of 8 week treatments</time_frame>
    <description>changes of UACR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in transforming growth factor beta (TGF-beta) between treatment arms</measure>
    <time_frame>baseline and the end of 8 week treatments</time_frame>
    <description>Changes of urinary excretion of transforming growth factor beta (TGF-beta)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in serum potassium and creatinine between treatment arms</measure>
    <time_frame>baseline and the end of 8 week treatments</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <condition>Proteinuria</condition>
  <arm_group>
    <arm_group_label>C - A - B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>(A) telmisartan 80 mg + aliskiren 300 mg - (B) telmisartan 80 mg + eplerenon 50 mg - (C) telmisartan 160 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B - A - C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>(A) telmisartan 80 mg + aliskiren 300 mg - (B) telmisartan 80 mg + eplerenon 50 mg - (C) telmisartan 160 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A - B - C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>(A) telmisartan 80 mg + aliskiren 300 mg - (B) telmisartan 80 mg + eplerenon 50 mg - (C) telmisartan 160 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aliskiren, eplerenon, telmisartan</intervention_name>
    <description>aliskiren (Rasilez 300 mg, Novartis Europharm eplerenon (Inspra 50 mg, Pfizer Europe) telmisartan (Micardis 80 mg, Boehringer Ingelheim)</description>
    <arm_group_label>C - A - B</arm_group_label>
    <arm_group_label>B - A - C</arm_group_label>
    <arm_group_label>A - B - C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18-65 years

          -  chronic non-diabetic proteinuric nephropathy

          -  chronic kidney disease stage 1-3

          -  stable proteinuria above 500 mg/24 hours

          -  blood pressure above 125/75 mmHg and below 150/95 mmHg

          -  no steroids or other immunosuppressive treatment for a minimum of six months before
             the study

        Exclusion Criteria:

          -  unstable coronary heart disease

          -  decompensated congestive heart failure in the previous 6 months

          -  episode of malignant hypertension or stroke in the history

          -  diabetes

          -  creatinine clearance below 30 ml/min

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bolesław Rutkowski, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Departmen of Nephrology, Transplantation adn Internal Medicine, Medical University of Gdańsk, Poland</affiliation>
  </overall_official>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 11, 2012</study_first_submitted>
  <study_first_submitted_qc>February 28, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 29, 2012</study_first_posted>
  <last_update_submitted>February 28, 2012</last_update_submitted>
  <last_update_submitted_qc>February 28, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 29, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Gdansk</investigator_affiliation>
    <investigator_full_name>Leszek Tylicki</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <keyword>aliskiren</keyword>
  <keyword>eplerenon</keyword>
  <keyword>telmisartan</keyword>
  <keyword>direct renin inhibitor</keyword>
  <keyword>ACE inhibitor</keyword>
  <keyword>mineralocorticoid inhibitor</keyword>
  <keyword>proteinuria</keyword>
  <keyword>chronic kidney diseases</keyword>
  <keyword>renin-angiotensin-aldosterone system</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Proteinuria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Eplerenone</mesh_term>
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

